Repeated-Dose High-Dose Ivermectin Pharmacokinetics and Safety in Children with Acute Dengue
6 affiliations
- 1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 2Molecular Biology of Dengue and Flaviviruses Research Team, Medical Molecular Biotechnology Research Group, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Khlong Luang, Pathum Thani Thailand
- 3Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj Hospital, Mahidol University, 12th Floor Adulyadejvikrom Building, Siriraj Hospital, 2 Wanglang Road, Bangkok Noi, Bangkok, 10700 Thailand
- 4Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
- 5Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
- 6Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine Siriraj Hospital, Mahidol University, 12th Floor Adulyadejvikrom Building, Siriraj Hospital, 2 Wanglang Road, Bangkok Noi, Bangkok, 10700 Thailand
Abstract
Background and Objective: Ivermectin has shown anti-dengue virus activity in experimental systems, and an adult dengue trial found faster clearance of circulating non-structural protein 1 (NS1) without improvement in viremia or clinical outcomes. Pediatric pharmacokinetic and safety data for repeated high-dose regimens remain limited. We characterized repeated-dose ivermectin pharmacokinetics and safety in children with acute uncomplicated dengue weighing ≥15 kg.
Methods: In this prospective, open-label, sequential dose-escalation study, children aged 1–15 years who presented within 72 h of fever onset and met the protocol laboratory-confirmation criteria for dengue received ivermectin 400 or 600 μg/kg once daily for 3 days. Noncompartmental analyses estimated exposure and peak concentrations from intensive plasma sampling. Exploratory analyses examined associations between exposure and viremia and NS1 trajectories during the first 48 h after dose 1; the study was not designed or powered to evaluate antiviral efficacy.
Results: All 24 children completed follow-up and experienced at least one adverse event; most events were consistent with acute dengue. Six participants (25%) experienced serious adverse events consisting of grade 4 neutropenia; all participants were clinically well, required no neutropenia-specific treatment, and showed improvement at the next available assessment or follow-up. No serious adverse event was assessed as related to ivermectin. One asymptomatic grade 1 QTc-prolongation adverse event was recorded and required no intervention. Exposure increased with dose: median 0–48-h area under the concentration–time curve (AUClast) was 1316.49 and 2129.41 ng·h/mL at 400 and 600 μg/kg, respectively, and corresponding maximum observed concentrations (Cmax) were 107.50 and 165.50 ng/mL. Dose-normalized parameters showed no clear relationship with body weight. Analyses confined to the first 48 h identified no clear exposure–response association with viremia or NS1 trajectories.
Conclusions: In children weighing ≥15 kg with acute uncomplicated dengue, ivermectin exposure increased with administered dose, while dose-normalized AUClast and Cmax showed no clear relationship with body weight across the studied range. Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN) therefore fills an important dengue-specific pediatric clinical pharmacology gap and provides repeated-dose exposure and safety reference data that may inform dose selection, exposure interpretation, and safety monitoring in future studies. The study was not designed to determine antiviral efficacy or clinical benefit.
Trial Registry: ClinicalTrials.gov: NCT03432442; first posted February 14, 2018.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40272-026-00771-4.
Related
- Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma
- Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis.
- Three-year Comparative Efficacy and Safety of Repeated Low-level Red-light Therapy and Orthokeratology for Myopia Control in Children
- Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions
- Natural products targeting mitochondrial homeostasis: a four-dimensional framework integrating dynamics, mitophagy, pharmacokinetics, and translational safety
BibTeX
@article{lapphra2026repeateddose,
title = {{Repeated-Dose High-Dose Ivermectin Pharmacokinetics and Safety in Children with Acute Dengue}},
author = {Keswadee Lapphra and Dumrong Mairiang and Joel Tarning and Dararat Prayongkul and Chunya Puttikhunt and Adisak Songjaeng and Tanapan Prommool and Nattaya Tangthawornchaikul and Kulkanya Chokephaibulkit and Panisadee Avirutnan},
journal = {Paediatric Drugs},
year = {2026},
month = sep,
doi = {10.1007/s40272-026-00771-4},
url = {https://doi.org/10.1007/s40272-026-00771-4},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Repeated-Dose High-Dose Ivermectin Pharmacokinetics and Safety in Children with Acute Dengue
AU - Keswadee Lapphra
AU - Dumrong Mairiang
AU - Joel Tarning
AU - Dararat Prayongkul
AU - Chunya Puttikhunt
AU - Adisak Songjaeng
AU - Tanapan Prommool
AU - Nattaya Tangthawornchaikul
AU - Kulkanya Chokephaibulkit
AU - Panisadee Avirutnan
PY - 2026
DA - 2026/09/22
JO - Paediatric Drugs
DO - 10.1007/s40272-026-00771-4
UR - https://doi.org/10.1007/s40272-026-00771-4
AB - Background and Objective: Ivermectin has shown anti-dengue virus activity in experimental systems, and an adult dengue trial found faster clearance of circulating non-structural protein 1 (NS1) without improvement in viremia or clinical outcomes. Pediatric pharmacokinetic and safety data for repeated high-dose regimens remain limited. We characterized repeated-dose ivermectin pharmacokinetics and safety in children with acute uncomplicated dengue weighing ≥15 kg. Methods: In this prospective, open-label, sequential dose-escalation study, children aged 1–15 years who presented within 72 h of fever onset and met the protocol laboratory-confirmation criteria for dengue received ivermectin 400 or 600 μg/kg once daily for 3 days. Noncompartmental analyses estimated exposure and peak concentrations from intensive plasma sampling. Exploratory analyses examined associations between exposure and viremia and NS1 trajectories during the first 48 h after dose 1; the study was not designed or powered to evaluate antiviral efficacy. Results: All 24 children completed follow-up and experienced at least one adverse event; most events were consistent with acute dengue. Six participants (25%) experienced serious adverse events consisting of grade 4 neutropenia; all participants were clinically well, required no neutropenia-specific treatment, and showed improvement at the next available assessment or follow-up. No serious adverse event was assessed as related to ivermectin. One asymptomatic grade 1 QTc-prolongation adverse event was recorded and required no intervention. Exposure increased with dose: median 0–48-h area under the concentration–time curve (AUClast) was 1316.49 and 2129.41 ng·h/mL at 400 and 600 μg/kg, respectively, and corresponding maximum observed concentrations (Cmax) were 107.50 and 165.50 ng/mL. Dose-normalized parameters showed no clear relationship with body weight. Analyses confined to the first 48 h identified no clear exposure–response association with viremia or NS1 trajectories. Conclusions: In children weighing ≥15 kg with acute uncomplicated dengue, ivermectin exposure increased with administered dose, while dose-normalized AUClast and Cmax showed no clear relationship with body weight across the studied range. Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN) therefore fills an important dengue-specific pediatric clinical pharmacology gap and provides repeated-dose exposure and safety reference data that may inform dose selection, exposure interpretation, and safety monitoring in future studies. The study was not designed to determine antiviral efficacy or clinical benefit. Trial Registry: ClinicalTrials.gov: NCT03432442; first posted February 14, 2018. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40272-026-00771-4.
SN - 1174-5878
SN - 1179-2019
ER -